C
rohn's disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBDs) that are associated with significant nutrient deficiencies and metabolic derangements at the time of diagnosis. 1 This is due to a combination of impaired absorption, increased utilization, decreased intake, effects of medication, and consequences of chronic inflammation. This combination leads to changes in body composition that can vary over the course of the disease. 2, 3 Diminished muscle mass has been reported in 60% of adults with CD compared with normal subjects. 4 Similar findings have been identified in pediatric patients with CD and UC with rates of muscle depletion reaching 93.6%. 5 Despite having a chronic level of inflammation and atrophy of muscle mass, there has been an increased prevalence of obesity in patients with CD. 6 Research has shown that adipose tissue may play a role in inflammation of IBD by release of adipokines, adipocyte stress response, and macrophage stimulation. 7 Obese patients with CD may have worse perianal disease, require more hospitalizations and have poorer surgical outcomes than matched nonobese patients with CD. 8, 9 They may also have a decreased response to commonly used medications such as anti-tumor necrosis factor-a (anti-TNF-a) biologic agents. 10 Little is known about the body composition of these obese patients with CD. It is possible that despite the high body mass, obese patients with CD are actually sarcopenic (low muscle mass) because of chronic inflammation and could benefit from nutritional intervention. Sarcopenic obesity has recently been identified as a negative predictor of survival in cancer patients, cirrhosis, and cardio-metabolic disease 11, 12 and may explain some of the poor outcomes in obese patients with CD.
There are various methods to estimate body composition. Abdominal computed tomography (CT) can be used to accurately assess body composition and is frequently obtained during the routine care of patients with IBD. An automated software program has been developed that allows quick and reliable segmentation of skeletal muscle and the visceral and subcutaneous adipose tissue from a single CT image or slice. Single slice measures at L3 vertebra strongly correlate with whole-body measures. Sarcopenia cutpoints have been identified using this software in subjects with cancer and cirrhosis that predict clinical outcomes. 13, 14 The primary aim of this study was to determine the prevalence of sarcopenia in normal-weight and overweight patients with IBD using abdominal CT in a cohort of patients with IBD starting an anti-TNF-a medication. Secondary aims included investigation of whether sarcopenic patients with IBD have differences in treatment response anti-TNF-a therapy compared with their nonsarcopenic counterparts and to examine the differences in serum markers of disease activity and nutritional status in this cohort.
MATERIALS AND METHODS
The IBD Center at Vanderbilt University Medical Center cares for approximately 7000 patients with IBD. The center has a dedicated IBD pharmacist who maintains a list of patients who start any anti-TNF-a medication (infliximab, adalimumab, or certolizumab) through the Center. This group of patients was selected for this study as they were believed to be at greatest risk for having an abnormal body composition due to moderate-tosevere disease. We reviewed all the patients on this list from August 2012 through December 2015. These patients' charts were retrospectively reviewed and included in the study if they had an abdominal CT at our institution within 3 months of the anti-TNFa medication initiation. Patients in whom we could not obtain an accurate height or weight within 3 months of CT or whom CT was unusable for body composition analysis were excluded.
For qualifying patients, we collected data on patient demographics, disease history, height, and weight, the Harvey Bradshaw Disease Activity Index (HBI), medications, serum markers of disease activity and nutrition, and clinical outcomes (Table 1) . These data points were collected at anti-TNF-a medication initiation and at 6 months. As this is a retrospective chart review, the data points were collected as part of routine patient care and were not necessarily standardized. This is particularly relevant for the height and weight which was obtained at intake to clinic appointments.
Identified abdominal CTs were analyzed via an automated version of Slice-O-Matic software (Version 4.3; TomoVision, Montreal, QC, Canada). A single cross-sectional CT slice at the L3 vertebra was used for segmentation of skeletal muscle, visceral, and subcutaneous adipose tissue. Our image analysis software is a noncommercialized automated version of Slice-o-Matic. This automation reduces the potential for user bias. In this software, the criterion for identification of skeletal muscle is a tissue density of 229 to +150 HU and for adipose tissue a tissue density of 230 to 2190 HU. Dr. H. J. Silver., co-investigator and director of the Vanderbilt Diet, Body Composition, and Human Metabolism CORE supervised the analyses and provided quality control.
We used skeletal muscle mass of ,38.5 cm 2 /m 2 for women and ,52.4 cm 2 /m 2 for men as sarcopenia cut points as previously defined. 15, 16 
Statistical Analysis
Statistical analyses were completed with STATA version 13.1 (College Station, TX). Descriptive data are reported as median (25, 75%) or N (%). A Mann-Whitney test was used for nonpaired analyses between 2 groups. A student's paired t test with unequal variance was used for patients' changes in disease activity and blood tests. Categorical data were analyzed with Pearson's x 2 test. Correlations were determined using Spearman's rank correlation. A multivariable logistic regression model was used to predict the identified outcomes.
Ethical Considerations
The study protocol was approved by the Vanderbilt University Institutional Review Board.
RESULTS
We reviewed 427 charts and identified a total of 90 patients starting a new anti-TNF-a agent that met the inclusion criteria. Our cohort was predominantly women (52%) with a median age of 35 (26, 50) and median body mass index (BMI) of 22. 5 (19, 27) . Most of the patients had CD (85%) whereas all the others had UC. Of the patients with CD, most patients had some small intestine involvement with the majority being ileocolonic (70%) followed by isolated small bowel (16%), colonic (9.3%), and gastroduodenal (1.3%) disease. Near half of our patients had a previous surgery (44%) and only 15% had been previously exposed to a biological agent. Thirty-three percent were on steroids and 44% on immunomodulators at the time of anti-TNF-a medication initiation. The average HBI before anti-TNF-a therapy was 6 (2, 9). Patients were started on infliximab (37%), adalimumab (43%), and certolizumab (10%).
The median time from anti-TNF-a medication initiation to CT was 15 days (29.25, 33). Almost half of our cohort was sarcopenic (45%) with a median skeletal muscle mass of 45 cm 2 /m 2 (40, 51). Sarcopenic subjects had a lower BMI and were (Table 2 ). There was no significant difference in rate of sarcopenia among those starting infliximab, adalimumab, or certolizumab. Approximately 1/3 of our cohort was overweight or obese based on BMI (Table 3) . Patients with sarcopenia had a lower median BMI than those without; however, 8/41 patients with sarcopenia would be classified as overweight or obese by BMI alone. There was a significant correlation between BMI and skeletal muscle mass (r ¼ 0.47, P , 0.001; Fig. 1 ). Baseline C reactive protein (CRP) was significantly higher, and albumin was significantly lower in those with sarcopenia (Table 4 ). There was no association with baseline erythrocyte sedimentation rate (ESR) or 25-OH vitamin D. We did not find a significant correlation between levels of CRP and albumin with absolute skeletal muscle mass in all subjects. There was an inverse relationship between skeletal muscle mass and CRP in patients with a BMI $25 (r ¼ 20.44, P ¼ 0.01).
Improvement in HBI score was isolated to patients without sarcopenia (Table 5 ). CRP and albumin improved overall but had a greater improvement in patients with sarcopenia compared with normal muscle mass. 25-OH Vitamin D improved only in those with normal muscle mass. There was a trend to gain weight in the entire cohort and those with normal muscle mass (1.5 kg, P ¼ 0.06 and 1.86 kg, P ¼ 0.07; respectively) but not in those with sarcopenia (1.14 kg, P ¼ 0.4).
In univariate analysis, sarcopenia was not associated with need for surgery, hospitalization, or new biological medication. In a subgroup analysis of overweight patients (BMI $ 25), all patients who had surgery were sarcopenic, and there was a significant association between surgery and sarcopenia (P ¼ 0.002). In multivariable analysis of previous surgery, sarcopenia, albumin, and CRP; previous surgery (OR 9.0, P ¼ 0.030) and CRP (OR 1.0, P ¼ 0.044) were significant predictors of the need for surgery in normal or underweight subjects (BMI , 25). In a multivariable analysis of overweight patients adjusting for CRP, previous surgery, and albumin, sarcopenia predicted need for surgery perfectly but was significantly limited by numbers (N ¼ 3). There was no significant difference in time to surgery (P ¼ 0.16) or hospitalization (P ¼ 0.60) between sarcopenic and nonsarcopenic subjects. We found similar results when excluding patients with UC.
DISCUSSION
Identification of malnutrition is recognized as a routine part of care for patients with IBD. Despite this many physicians struggle with identifying malnutrition in patients, especially in those who have a BMI greater than normal. Overweight and obesity has increased significantly in the US population over the past 3 decades, and it is not surprising that we are seeing similar trends in our patients with IBD. Little is known about the type of malnutrition present in overweight or obese patients with IBD.
Our cohort was predominantly ileocolonic CD, many of whom had previous surgeries, which is reflective of the population we see in our tertiary care center IBD clinic. We believe that these patients are at high risk of malnutrition and need appropriate nutrition assessment. Sarcopenia is an objective marker associated with malnutrition. In this study, we identified a high prevalence of sarcopenia (45%) in patients with IBD starting anti-TNF-a therapy at our Center. In this same cohort only 23% were classified as underweight and would be identified as undernourished if only assessed by BMI. This supports the importance of alternate methods to identify patients with IBD who are malnourished, especially with sarcopenic obesity. Cross-sectional abdominal imaging is a common part of monitoring disease activity in patients with IBD, and calculation of muscle mass could easily be added to imaging protocols. This would provide the physician with an objective parameter to assist with nutrition care.
Interestingly, 20% of patients with sarcopenia in this cohort were classified as overweight or obese by BMI. Many times the Data are displayed as N (%). There was a significant difference in BMI category between the sarcopenic and nonsarcopenic patients (P ¼ 0.002).
nutrition needs of these patients are not addressed because of a patient's body habitus or goals for weight loss. Physicians caring for patients with IBD need to take this into consideration when providing medical nutrition therapy to these patients. These patients may benefit from high protein supplementation with lower total calorie goals as is currently recommended in nutrition guidelines for enteral and parenteral nutrition in obese ill patients. 15 Whether or not the anti-TNF-a therapy can reverse sarcopenia in the overweight and obese population without nutrition support is unknown. A future study identifying reversal of sarcopenia in patients undergoing new biological therapy with and without protein supplementation would be of interest. All overweight and obese patients who had surgery were sarcopenic. Our numbers are very small, but it is interesting that only those subjects with BMI $ 25 with low muscle mass required a surgery after a new anti-TNF-a initiation. In these patients, sarcopenia may be a better predictor than serum albumin, a biomarker that is commonly used by surgeons to assess nutritional and protein status before surgery. In this cohort, we did not have data on surgical outcomes. A previous study has shown sarcopenia to be a predictor of post-op complications. 16 This study was conducted in a Chinese cohort with a significantly lower average BMI compared with our cohort, and they did not comment on outcomes in overweight sarcopenic patients. A follow-up study would be to investigate surgical outcomes in sarcopenic and nonsarcopenic overweight IBD subjects to determine the impact of nutritional intervention. The major limitation of our study is that it was retrospective and uncontrolled. The total number of patients was small, and there were a limited number of subjects who were obese and overweight. We did not collect data on dosage of corticosteroids or exposure to nutrition support which can affect body composition. We allowed a broad time frame of 3 months to help capture a sufficient number of patients who had CT close to the start of a new anti-TNF-a agent which may have influenced outcome measures. Having said this, half of the patients had a scan performed within 15 days of initiating therapy. Our outcome predictions were significantly limited by low numbers of patients needing surgery, new biologic medication or hospitalization. Because our numbers were limited, a larger study is needed to validate the association between sarcopenia in overweight patients with IBD and need for surgery before strong conclusions can be made. In addition, this was a selected cohort of patients with mainly moderate-to-severe ileocolonic CD starting a new biological therapy. Although this is representative of the population seen at our institution, this represents a selection bias and the generalizability of our findings to all patients with IBD would require additional research. Controlled cohorts should be examined to assess the impact of body composition and sarcopenia on various treatments, especially surgical interventions. Ideally prospective studies should be done to compare the impact of nutrition interventions in the care of patients with IBD with malnutrition and various alterations in body composition. A prospective study would also provide an opportunity to perform repeat CT dedicated to the assessment of body composition so that it could be precisely timed for the start and end of an intervention.
In summary, we believe it is important to identify malnutrition in all patients with IBD. The use of objective measures, such as sarcopenia, can help identify malnutrition in the overweight patients with IBD that may be overlooked by traditional assessment. This study identified sarcopenia in 20% of overweight patients with IBD and suggested that they are more likely to require surgery than their nonsarcopenic counterparts. Abdominal CTs, which are commonly obtained in patients with IBD when starting new medical therapy or when surgery is considered, may be used to analyze body composition and identify patients with low muscle mass. These results may help improve the care of patients as those with malnutrition are more likely to benefit from medical nutrition therapy.
